Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 12INDUSTRY 6NETWORK 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Specimen Handling 19Cyclophosphamide 18Magnetic Resonance Spectroscopy 17Vincristine 16Dexamethasone 15Radiotherapy 14Cisplatin 14Radiation 12Etoposide 11Doxorubicin 11Radiotherapy, Intensity-Modulated 10Carboplatin 10durvalumab 9Paclitaxel 9Cytarabine 8Temozolomide 7Rituximab 7Radiotherapy, Conformal 7Prednisone 7Lenalidomide 7Irinotecan 7Gemcitabine 7Fluorouracil 7Docetaxel 7Bortezomib 7Biopsy 7daratumumab 6Platinum 6Leucovorin 6Capecitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × darolutamide × Clear all
NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT02972060 2025-09-19

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
61 enrolled
Genitourinary

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡